|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | G01N 33/50 | |
| G01N 33/564 |
| (11) | Number of the document | 2425250 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10716450.1 |
| Date of filing the European patent application | 2010-04-27 | |
| (97) | Date of publication of the European application | 2012-03-07 |
| (45) | Date of publication and mention of the grant of the patent | 2014-02-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/032572 |
| Date | 2010-04-27 |
| (87) | Number | WO 2010/126890 |
| Date | 2010-11-04 |
| (30) | Number | Date | Country code |
| 173138 P | 2009-04-27 | US |
| (72) |
SHERIDAN III, James Peter, US
|
| (73) |
AbbVie Biotherapeutics Inc.,
1500 Seaport Boulevard, Redwood City, CA 94063,
US
|
| (54) | METHODS FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS |
| METHODS FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTS |